High grade urothelial carcinoma. Credit: TexasPathologistMSW.

Astellas Pharma and Seattle Genetics have started dosing in the Phase Ib EV-103 clinical trial of enfortumab vedotin combined with pembrolizumab or atezolizumab as first or second line treatment of locally advanced or metastatic urothelial cancer.

Enfortumab vedotin is an antibody-drug conjugate (ADC) being developed to target Nectin-4 with the delivery of cell-killing agent monomethyl auristatin E (MMAE).

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The drug candidate comprises an anti-Nectin-4 monoclonal antibody linked with the MMAE.

Pembrolizumab and atezolizumab are different types of immune checkpoint inhibitors (CPI).

The single arm, open label, multi-centre Phase Ib trial will involve administration of enfortumab vedotin for one and two weeks of every three-week cycle. Pembrolizumab or atezolizumab will be given during week one of the cycle.

“We are committed to exploring additional ways to potentially address the unmet needs of the urothelial cancer community.”

EV-103 will evaluate the investigational candidate in up to 85 patients ineligible for first line cisplatin-based chemotherapy or have progressed after a regimen, including platinum-based chemotherapy.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Astellas Pharma oncology development senior vice-president and global therapeutic area head Steven Benne said: “Many patients do not respond to or relapse after treatment with CPIs, and we are committed to exploring additional ways to potentially address the unmet needs of the urothelial cancer community.”

The primary objective of the trial is the safety and tolerability of enfortumab vedotin in combination with the CPI treatment.

During the trial, secondary endpoints such as recommended dose in combination with CPIs, overall response rate (ORR), duration of response (DOR), progression-free survival (PFS) and overall survival (OS) will also be monitored.

Enfortumab vedotin is being further assessed as a monotherapy in the EV-201 trial for advanced urothelial cancer.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Science 37 has won the Research and Development Award in the Site Innovation category for its FDA inspected Direct-to-Patient Site model, delivering nationwide access, faster enrollment and higher retention. Explore how its virtual-first, in home approach is reshaping trial operations and accelerating time to data-driven decisions..

Discover the Impact